Literature DB >> 14612567

Functional identification of distinct sets of antitumor activities mediated by the FKBP gene family.

Sylvia Fong1, Leslie Mounkes, Yong Liu, Michael Maibaum, Eric Alonzo, Pierre-Yves Desprez, Ann D Thor, Mohammed Kashani-Sabet, Robert J Debs.   

Abstract

Assigning biologic function to the many sequenced but still uncharacterized genes remains the greatest obstacle confronting the human genome project. Differential gene expression profiling routinely detects uncharacterized genes aberrantly expressed in conditions such as cancer but cannot determine which genes are functionally involved in such complex phenotypes. Integrating gene expression profiling with specific modulation of gene expression in relevant disease models can identify complex biologic functions controlled by currently uncharacterized genes. Here, we used systemic gene transfer in tumor-bearing mice to identify novel antiinvasive and antimetastatic functions for Fkbp8, and subsequently for Fkbp1a. Fkbp8 is a previously uncharacterized member of the FK-506-binding protein (FKBP) gene family down-regulated in aggressive tumors. Antitumor effects produced by Fkbp1a gene expression are mediated by cellular pathways entirely distinct from those responsible for antitumor effects produced by Fkbp1a binding to its bacterially derived ligand, rapamycin. We then used gene expression profiling to identify syndecan 1 (Sdc1) and matrix metalloproteinase 9 (MMP9) as genes directly regulated by Fkbp1a and Fkbp8. FKBP gene expression coordinately induces the expression of the antiinvasive Sdc1 gene and suppresses the proinvasive MMP9 gene. Conversely, short interfering RNA-mediated suppression of Fkbp1a increases tumor cell invasion and MMP9 levels, while down-regulating Sdc1. Thus, syndecan 1 and MMP9 appear to mediate the antiinvasive and antimetastatic effects produced by FKBP gene expression. These studies show that uncharacterized genes differentially expressed in metastatic cancers can play important functional roles in the metastatic phenotype. Furthermore, identifying gene regulatory networks that function to control tumor progression may permit more accurate modeling of the complex molecular mechanisms of this disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14612567      PMCID: PMC283578          DOI: 10.1073/pnas.2332307100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

Review 1.  Rapamycin in transplantation: a review of the evidence.

Authors:  R N Saunders; M S Metcalfe; M L Nicholson
Journal:  Kidney Int       Date:  2001-01       Impact factor: 10.612

2.  Identification of gene function and functional pathways by systemic plasmid-based ribozyme targeting in adult mice.

Authors:  Mohammed Kashani-Sabet; Yong Liu; Sylvia Fong; Pierre-Yves Desprez; Shuqing Liu; Guanghuan Tu; Mehdi Nosrati; Chakkrapong Handumrongkul; Denny Liggitt; Ann D Thor; Robert J Debs
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

3.  Metalloproteinase expression and prognosis in soft tissue sarcomas.

Authors:  M S Benassi; G Gamberi; G Magagnoli; L Molendini; P Ragazzini; M Merli; F Chiesa; A Balladelli; M Manfrini; F Bertoni; M Mercuri; P Picci
Journal:  Ann Oncol       Date:  2001-01       Impact factor: 32.976

4.  Accurate identification of experimental pulmonary metastases.

Authors:  H Wexler
Journal:  J Natl Cancer Inst       Date:  1966-04       Impact factor: 13.506

5.  FKBP12, the 12-kDa FK506-binding protein, is a physiologic regulator of the cell cycle.

Authors:  B Aghdasi; K Ye; A Resnick; A Huang; H C Ha; X Guo; T M Dawson; V L Dawson; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-20       Impact factor: 11.205

6.  Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes.

Authors:  J Liu; J D Farmer; W S Lane; J Friedman; I Weissman; S L Schreiber
Journal:  Cell       Date:  1991-08-23       Impact factor: 41.582

7.  The FKBP-associated protein FAP48 is an antiproliferative molecule and a player in T cell activation that increases IL2 synthesis.

Authors:  Ulrike Krummrei; Etienne-Emile Baulieu; Béatrice Chambraud
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-25       Impact factor: 11.205

Review 8.  Mammalian target of rapamycin: a new molecular target for breast cancer.

Authors:  Monica M Mita; Alain Mita; Eric K Rowinsky
Journal:  Clin Breast Cancer       Date:  2003-06       Impact factor: 3.225

9.  Rapamycin is an effective inhibitor of human renal cancer metastasis.

Authors:  Fu L Luan; Ruchuang Ding; Vijay K Sharma; W James Chon; Milagros Lagman; Manikkam Suthanthiran
Journal:  Kidney Int       Date:  2003-03       Impact factor: 10.612

Review 10.  CCI-779 Wyeth.

Authors:  Laurie Elit
Journal:  Curr Opin Investig Drugs       Date:  2002-08
View more
  15 in total

1.  Genomic profiling of kidney ischemia-reperfusion reveals expression of specific alloimmunity-associated genes: Linking "immune" and "nonimmune" injury events.

Authors:  D N Grigoryev; M Liu; C Cheadle; K C Barnes; H Rabb
Journal:  Transplant Proc       Date:  2006-12       Impact factor: 1.066

2.  Effect of intraportal infusion of tacrolimus on ischaemic reperfusion injury in orthotopic liver transplantation: a randomized controlled trial.

Authors:  Ivan Kristo; Julia Wilflingseder; Alexander Kainz; Julian Marschalek; Thomas Wekerle; Ferdinand Mühlbacher; Rainer Oberbauer; Martin Bodingbauer
Journal:  Transpl Int       Date:  2011-06-14       Impact factor: 3.782

3.  Bcl-2 regulator FKBP38 is activated by Ca2+/calmodulin.

Authors:  Frank Edlich; Matthias Weiwad; Frank Erdmann; Jörg Fanghänel; Franziska Jarczowski; Jens-Ulrich Rahfeld; Gunter Fischer
Journal:  EMBO J       Date:  2005-06-30       Impact factor: 11.598

4.  The peptidyl prolyl cis/trans isomerase FKBP38 determines hypoxia-inducible transcription factor prolyl-4-hydroxylase PHD2 protein stability.

Authors:  Sandra Barth; Jutta Nesper; Philippe A Hasgall; Renato Wirthner; Katarzyna J Nytko; Frank Edlich; Dörthe M Katschinski; Daniel P Stiehl; Roland H Wenger; Gieri Camenisch
Journal:  Mol Cell Biol       Date:  2007-03-12       Impact factor: 4.272

5.  FKBP38 protects Bcl-2 from caspase-dependent degradation.

Authors:  Bo-Hwa Choi; Lin Feng; Ho Sup Yoon
Journal:  J Biol Chem       Date:  2010-02-05       Impact factor: 5.157

Review 6.  Unraveling the complex genetics of neural tube defects: From biological models to human genomics and back.

Authors:  Paul Wolujewicz; John W Steele; Julia A Kaltschmidt; Richard H Finnell; Margaret Elizabeth Ross
Journal:  Genesis       Date:  2021-10-29       Impact factor: 2.487

7.  A critical role of noggin in developing folate-nonresponsive NTD in Fkbp8 -/- embryos.

Authors:  Takao Tsurubuchi; Elise V Allender; M Rizwan Siddiqui; Kyu-Won Shim; Shunsuke Ichi; Vanda Boshnjaku; Barbara Mania-Farnell; Guifa Xi; Richard H Finnell; David G McLone; Tadanori Tomita; C S Mayanil
Journal:  Childs Nerv Syst       Date:  2014-05-10       Impact factor: 1.475

8.  Signal peptide peptidase promotes tumor progression via facilitating FKBP8 degradation.

Authors:  Fu-Fei Hsu; Yi-Tai Chou; Ming-Tsai Chiang; Fu-An Li; Chi-Tai Yeh; Wei-Hwa Lee; Lee-Young Chau
Journal:  Oncogene       Date:  2018-10-22       Impact factor: 9.867

9.  Analysis of metagene portraits reveals distinct transitions during kidney organogenesis.

Authors:  Igor F Tsigelny; Valentina L Kouznetsova; Derina E Sweeney; Wei Wu; Kevin T Bush; Sanjay K Nigam
Journal:  Sci Signal       Date:  2008-12-09       Impact factor: 8.192

10.  FKBP8 variants are risk factors for spina bifida.

Authors:  Tian Tian; Xuanye Cao; Sung-Eun Kim; Ying Linda Lin; John W Steele; Robert M Cabrera; Menuka Karki; Wei Yang; Nicholas J Marini; Ethan N Hoffman; Xiao Han; Cindy Hu; Linlin Wang; Bogdan J Wlodarczyk; Gary M Shaw; Aiguo Ren; Richard H Finnell; Yunping Lei
Journal:  Hum Mol Genet       Date:  2020-11-04       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.